Ensign Peak Advisors Inc Reduces Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Ensign Peak Advisors Inc lessened its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,084 shares of the specialty pharmaceutical company’s stock after selling 1,245 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Jazz Pharmaceuticals were worth $2,997,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Rise Advisors LLC lifted its position in Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 203 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 269 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the period. Gladius Capital Management LP purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth approximately $33,000. Finally, Assetmark Inc. increased its position in Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 119 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on JAZZ. Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. The Goldman Sachs Group began coverage on Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target on the stock. Finally, Piper Sandler dropped their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

Jazz Pharmaceuticals Stock Up 2.2 %

JAZZ opened at $110.19 on Friday. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $137.38. The stock has a market capitalization of $6.95 billion, a P/E ratio of 22.72, a P/E/G ratio of 1.36 and a beta of 0.57. The business has a 50 day simple moving average of $110.98 and a 200-day simple moving average of $110.86.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. On average, equities analysts anticipate that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.